By Tony Fong

NEW YORK (GenomeWeb News) – Five years after its founding, and less than one year after launching its first product, molecular diagnostics firm Crescendo Bioscience is shifting to full commercialization mode for its test targeting rheumatoid arthritis.

But unlike many other startups that are transitioning from the technology development phase, the South San Francisco, Calif.-based company may not have to worry about how to provide its investors a return on its investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.